UBRELVY® (ubrogepant)

  • Home
  • UBRELVY® (ubrogepant)

UBRELVY® (ubrogepant) Please see Patient Information here: abbv.ie/00ac64 Follow us for all the latest updates. All rights reserved.

UBRELVY® (ubrogepant) is the first CGRP (calcitonin gene-related peptide) receptor antagonist, FDA approved for the acute treatment of migraine with or without aura in adults. UBRELVY® and its design are registered trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.

© 2023 AbbVie.

Click abbv.ie/00ac64 to see UBRELVY Patient Information.
18/09/2023

Click abbv.ie/00ac64 to see UBRELVY Patient Information.

Address


Website

Alerts

Be the first to know and let us send you an email when UBRELVY® (ubrogepant) posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

  • Want your practice to be the top-listed Clinic?

Share